Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	115
Overall Study	STARTED	Ramelteon SL 0.1 mg	128
Overall Study	STARTED	Ramelteon SL 0.4 mg	124
Overall Study	STARTED	Ramelteon SL 0.8 mg	123
Overall Study	Safety Set - Received Treatment	Placebo	115
Overall Study	Safety Set - Received Treatment	Ramelteon SL 0.1 mg	127
Overall Study	Safety Set - Received Treatment	Ramelteon SL 0.4 mg	124
Overall Study	Safety Set - Received Treatment	Ramelteon SL 0.8 mg	123
Overall Study	COMPLETED	Placebo	86
Overall Study	COMPLETED	Ramelteon SL 0.1 mg	100
Overall Study	COMPLETED	Ramelteon SL 0.4 mg	97
Overall Study	COMPLETED	Ramelteon SL 0.8 mg	96
Overall Study	NOT COMPLETED	Placebo	29
Overall Study	NOT COMPLETED	Ramelteon SL 0.1 mg	28
Overall Study	NOT COMPLETED	Ramelteon SL 0.4 mg	27
Overall Study	NOT COMPLETED	Ramelteon SL 0.8 mg	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01467700/flow